谈AI 谋出海 话未来 近90家上海辖区上市公司与投资者“热聊”

Core Insights - The event highlighted the integration of AI technology in innovative drug development services, with companies like Medici focusing on building an AI-based preclinical research platform [1][2] - There is a strong emphasis on international market expansion among Shanghai-listed companies, with many exploring overseas manufacturing and localized operations to seek new growth [4][5] Group 1: AI and Robotics Developments - Medici's CEO emphasized the importance of AI in drug development, aiming to enhance their one-stop innovative drug research platform [2] - Cambridge Technology has begun small-scale supply of its 1.6T optical modules, with expectations for mass shipments by Q1 2026 [2] - Yongmaotai is collaborating with a leading humanoid robotics company to innovate in robotics technology and commercial applications [2][3] Group 2: International Market Expansion - Companies are actively pursuing internationalization strategies, with Ailis focusing on global clinical trials for its drug, Vomeletinib, in collaboration with ArriVent [4] - Zijiang Enterprises has operational overseas factories, including a 49% stake in an Ethiopian company and a fully-owned subsidiary in Vietnam [5] - Light Dairy is enhancing its international business through its New Zealand subsidiary, focusing on high-nutrition products for the Chinese and Southeast Asian markets [5] Group 3: Future Technology and Product Development - Yongmaotai plans to develop core components for robots and electric drive systems, leveraging technological innovation for product upgrades [3] - Companies are exploring the application of AI in their business operations, with Zhonggu Logistics actively seeking to implement smart technologies [3] - Pioneering companies like Pioneering Technology are enhancing their global market share in home energy storage by leveraging their brand reputation in Europe [6]